France· FR:69232595
EVUSHELD 150 mg + 150 mg, solution injectable
A medicinal product containing cilgavimab + tixagévimab, registered in France by ASTRAZENECA AB.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- CILGAVIMAB + TIXAGÉVIMAB
- Manufacturer
- ASTRAZENECA AB
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip1334009302542641 flacon(s) en verre de 1,5 ml - 1 flacon(s) en verre de 1,5 ml
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Cilgavimab + tixagévimab in 3 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/61f93658-bb5d-4125-8ec3-d7dc0a15dadd GET /v1/drugs/61f93658-bb5d-4125-8ec3-d7dc0a15dadd?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "69232595",
"date_amm": "2022-03-25",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/22/1651",
"substance": "CILGAVIMAB + TIXAGÉVIMAB",
"statut_amm": "Autorisation abrogée",
"statut_bdm": "Warning disponibilité",
"forme_pharmaceutique": "solution injectable et solution injectable",
"voies_administration": "intramusculaire",
"etat_commercialisation": "Non commercialisée",
"surveillance_renforcee": "Oui"
}See everything about cilgavimab + tixagévimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.